European Heart Journal

دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه

ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
~~قیمت : 3,800,000 تومان~~
قیمت ویژه : 1,900,000تومان

سفارش

The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies

Filippo Crea

doi : 10.1093/eurheartj/ehab554

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3029–3032

خرید پکیج و مشاهده آنلاین مقاله

Mark Nicholls speaks to Professor Eric Durand and Professor Rémi Sabatier about Europe’s first remote robotic-assisted angioplasty procedure

Mark Nicholls

doi : 10.1093/eurheartj/ehab085

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3033–3035

خرید پکیج و مشاهده آنلاین مقاله

Syrian Cardiovascular Association: Small Steps towards a Bright Horizon

Amr Abdin, MD, FESC, FHFA, Asim Katbeh, MD, PhD, FESC and Yassin Bani Marjeh, MD

doi : 10.1093/eurheartj/ehab126

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3035–3037

خرید پکیج و مشاهده آنلاین مقاله

Herbal medicine in cardiovascular medicine: a discussion of herbal medications described by the Persian physician, Avicenna

Bahareh Sadat Yousefsani, Amirhossein Jamshidi, Majid Dadmehr

doi : 10.1093/eurheartj/ehab053

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3037–3039

خرید پکیج و مشاهده آنلاین مقاله

How a new drug is born

Andrea Caporali, Steven Fawell, Maurizio Scaltriti

doi : 10.1093/eurheartj/ehab076

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3039–3041

خرید پکیج و مشاهده آنلاین مقاله

A SPRINT towards tighter control of blood pressure in hypertension

Massimo Volpe, Carlo Patrono

doi : 10.1093/eurheartj/ehab400

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3042–3043

خرید پکیج و مشاهده آنلاین مقاله

The tobacco endgame—eradicating a worsening epidemic: A Joint Opinion From the American College of Cardiology, American Heart Association, European Society of Cardiology, and the World Heart Federation

Jeffrey Willett, Stephan Achenbach, Fausto J Pinto, Athena Poppas, Mitchell S V Elkind

doi : 10.1093/eurheartj/ehab245

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3044–3048

خرید پکیج و مشاهده آنلاین مقاله

Statin associated lower cancer risk and related mortality in patients with heart failure

Qing-Wen Ren, Si-Yeung Yu, Tiew-Hwa Katherine Teng, Xue Li, Ka-Shing Cheung, Mei-Zhen Wu, Hang-Long Li, Pui-Fai Wong, Hung-Fat Tse, Carolyn S P Lam, Kai-Hang Yiu

doi : 10.1093/eurheartj/ehab325

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3049–3059

Patients with heart failure (HF) have an increased risk of incident cancer. Data relating to the association of statin use with cancer risk and cancer-related mortality among patients with HF are sparse.

خرید پکیج و مشاهده آنلاین مقاله

Decoding the link between heart failure and incident cancer

Sanjay Divakaran, Anju Nohria

doi : 10.1093/eurheartj/ehab482

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3060–3062

خرید پکیج و مشاهده آنلاین مقاله

Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy

Luis R Lopes, Soledad Garcia-Hern?ndez, Massimiliano Lorenzini, Marta Futema, Olga Chumakova, Dmitry Zateyshchikov, Maria Isidoro-Garcia, Eduardo Villacorta, Luis Escobar-Lopez, Pablo Garcia-Pavia, Raquel Bilbao, David Dobarro, Maria Sandin-Fuentes, Claudio Catalli, Blanca Gener Querol, Ainhoa Mezcua, Jose Garcia Pinilla, Torsten Bloch Rasmussen, Ana Ferreira-Aguar, Pablo Revilla-Mart?, Maria Teresa Basurte Elorz, Alicia Bautista Paves, Juan Ramon Gimeno, Ana Virginia Figueroa, Raul Franco-Gutierrez, Maria Eugenia Fuentes-Ca?amero, Marina Martinez Moreno, Martin Ortiz-Genga, Jesus Piqueras-Flores, Karina Analia Ramos, Ainars Rudzitis, Luis Ruiz-Guerrero, Ricardo Stein, Mayte Triguero-Bochar?n, Luis de la Higuera, Juan Pablo Ochoa, Dad Abu-Bonsrah, Cecilia Y T Kwok, Jacob B Smith, Enzo R Porrello, Mohammed M Akhtar, Joanna Jager, Michael Ashworth, Petros Syrris, David A Elliott, Lorenzo Monserrat, Perry M Elliott

doi : 10.1093/eurheartj/ehab424

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3063–3073

The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies.

خرید پکیج و مشاهده آنلاین مقاله

ALPK3: a full spectrum cardiomyopathy gene?

Roddy Walsh, Connie R Bezzina

doi : 10.1093/eurheartj/ehab415

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3074–3077

خرید پکیج و مشاهده آنلاین مقاله

PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction

Lorenzo Da Dalt, Laura Castiglioni, Andrea Baragetti, Matteo Audano, Monika Svecla, Fabrizia Bonacina, Silvia Pedretti, Patrizia Uboldi, Patrizia Benzoni, Federica Giannetti, Andrea Barbuti, Fabio Pellegatta, Serena Indino, Elena Donetti, Luigi Sironi, Nico Mitro, Alberico Luigi Catapano, Giuseppe Danilo Norata

doi : 10.1093/eurheartj/ehab431

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3078–3090

PCSK9 is secreted into the circulation, mainly by the liver, and interacts with low-density lipoprotein receptor (LDLR) homologous and non-homologous receptors, including CD36, thus favouring their intracellular degradation. As PCSK9 deficiency increases the expression of lipids and lipoprotein receptors, thus contributing to cellular lipid accumulation, we investigated whether this could affect heart metabolism and function.

خرید پکیج و مشاهده آنلاین مقاله

Heart to heart with PCSK9

Kevin Chemello, Ali K Jaafar, Gilles Lambert

doi : 10.1093/eurheartj/ehab480

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3091–3093

خرید پکیج و مشاهده آنلاین مقاله

Peripartum cardiomyopathy: from genetics to management

Karen Sliwa, Johann Bauersachs, Zolt Arany, Timothy F Spracklen, Denise Hilfiker-Kleiner

doi : 10.1093/eurheartj/ehab458

European Heart Journal, Volume 42, Issue 32, 21 August 2021, Pages 3094–3102

Peripartum cardiomyopathy (PPCM) is a disease that occurs globally in all ethnic groups and should be suspected in any peripartum women presenting with symptoms and signs of heart failure, towards the end of pregnancy or in the months following delivery, with confirmed left ventricular dysfunction. After good history taking, all women should be thoroughly assessed, and alternative causes should be excluded. Urgent cardiac investigations with electrocardiogram and natriuretic peptide measurement (if available) should be performed. Echocardiography follows as the next step in investigation. Patients with abnormal cardiac investigations should be urgently referred to a cardiology team for expert management. Referral for genetic work-up should be considered if there is a family history of cardiomyopathy or sudden death. PPCM is a disease with substantial maternal and neonatal morbidity and mortality. Maternal mortality rates range widely, from 0% to 30%, depending on the ethnic background and geographic region. Just under half of women experience myocardial recovery. Remarkable advances in the comprehension of the pathogenesis and in patient management and therapy have been achieved, largely due to team efforts and close collaboration between basic scientists, cardiologists, intensive care specialists, and obstetricians. This review summarizes current knowledge of PPCM genetics, pathophysiology, diagnostic approach, management, and outcome.

خرید پکیج و مشاهده آنلاین مقاله